Evidence map›Paper›PMID 39762727›Full record

ArticleBMC cardiovascular disorders2025

Alantolactone mitigates the elevation of blood pressure in mice induced by angiotensin II by inhibiting calcium channel activation.

Ruqiang Yuan, Mingjing Gao, Hu Xu, Qing Liang, Lei Qian, Yali Wang, Houli Zhang, Erjiao Qiang, Weijing Yun

Abstract read
In one paragraph

Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. L-Type Voltage-Gated CaMedical sciences (Basel, Switzerland) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ruqiang Yuan *Advanced Institute for Medical Sciences, Dalian Medical University, Dalian, 116044, China.
Mingjing Gao *Department of Pharmacy, Dalian Port Hospital, Dalian, 116001, China.
Hu Xu *Wuhu Hospital and Health Science Center, East China Normal University, Shanghai, 200241, China.
Qing LiangAdvanced Institute for Medical Sciences, Dalian Medical University, Dalian, 116044, China.
Lei QianAdvanced Institute for Medical Sciences, Dalian Medical University, Dalian, 116044, China.
Yali WangAdvanced Institute for Medical Sciences, Dalian Medical University, Dalian, 116044, China.
Houli ZhangCollege of Pharmacy, Dalian Medical University, Dalian, 116044, China. houlizh@163.com.
Erjiao QiangDepartment of Pathology, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200080, China. qiangerjiao@126.com.
Weijing YunAdvanced Institute for Medical Sciences, Dalian Medical University, Dalian, 116044, China. yunweijing@dmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe dried root of Inula helenium L., known as Inulae Radix in Mongolian medicine, is a widely used heat-clearing plant drug within the Asteraceae family. Alantolactone (ATL), a compound derived from Inulae Radix, is a sesquiterpene lactone with a range of biological activities. However, there is a lack of studies investigating its effectiveness in the treatment of hypertension. The aim of this study is to explore the regulatory effect of alantolactone on blood pressure and its underlying mechanism. METHODS AND

resultsNetwork pharmacology analysis suggested that ATL had a potential therapeutic effect on hypertension induced by angiotensin II (Ang II). Subsequently, the results of animal experiments demonstrated that ATL could suppress the increase in blood pressure caused by Ang II. Vascular ring experiments indicated that ATL could inhibit the vascular contractions induced by Ang II, Phenylephrine, and Ca

conclusionsATL exerted an antihypertensive effect by inhibiting the activation of L-type VGCC and reducing calcium influx.

Indexed as

Angiotensin IIAntihypertensive AgentsBlood PressureCalcium Channel BlockersDisease Models, AnimalHypertensionLactonesMolecular Docking SimulationSesquiterpenes, EudesmaneAnimalsCalcium Channels, L-TypeCalcium SignalingMaleMiceMice, Inbred C57BLMuscle, Smooth, VascularalantolactoneAngiotensin IIAntihypertensive AgentsCalcium Channel BlockersCalcium Channels, L-TypeLactonesSesquiterpenes, EudesmaneAlantolactoneCalcium influxHypertensionVoltage-gated Calcium Channels

Identifiers

PMID39762727
PMCPMC11702132

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.